A publication in Nature in April 2026 reports that N-desethyl-fluornitrazene (DFNZ), a modified nitazene and µ-opioid receptor (MOR) superagonist, produced potent analgesia in rodents with less respiratory depression, weaker dopamine-linked reward signaling, lower withdrawal burden, and no clear tolerance or MOR downregulation. The study challenges the usual assumption that very high MOR efficacy must inevitably
How the opioid superagonist DFNZ challenges pain medicine originally appeared in KevinMD.com.
Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.